Strs Ohio Purchases Shares of 16,445 Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Strs Ohio has acquired 16,445 shares of Jazz Pharmaceuticals PLC, valued at approximately $2,042,000, according to their recent SEC filing.
• Institutional investors and hedge funds collectively own 89.14% of Jazz Pharmaceuticals' stock, indicating significant institutional interest in the company.
• Recent analyst ratings upgrades have improved Jazz Pharmaceuticals' price targets, with Royal Bank of Canada increasing their target to $151.00 and Truist Financial raising it to $205.00.

Strs Ohio purchased a new stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 16,445 shares of the specialty pharmaceutical company's stock, valued at approximately $2,042,000.

A number of other large investors have also recently modified their holdings of JAZZ. Cetera Investment Advisers purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $1,243,000. Deutsche Bank AG increased its position in shares of Jazz Pharmaceuticals by 4.0% during the fourth quarter. Deutsche Bank AG now owns 16,012 shares of the specialty pharmaceutical company's stock worth $1,972,000 after purchasing an additional 609 shares in the last quarter. Focus Partners Wealth purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at $551,000. Nuveen Asset Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 1.8% during the fourth quarter. Nuveen Asset Management LLC now owns 468,346 shares of the specialty pharmaceutical company's stock valued at $57,677,000 after buying an additional 8,448 shares during the last quarter. Finally, Nomura Holdings Inc. grew its holdings in shares of Jazz Pharmaceuticals by 218.3% during the fourth quarter. Nomura Holdings Inc. now owns 8,022 shares of the specialty pharmaceutical company's stock valued at $988,000 after buying an additional 5,502 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on JAZZ shares. Zacks Research raised shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a "buy" rating in a report on Thursday, August 28th. Royal Bank Of Canada boosted their price objective on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a report on Thursday, August 28th. The Goldman Sachs Group upped their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a report on Friday, August 29th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $178.67.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock traded down $2.89 during mid-day trading on Friday, hitting $128.30. 1,488,638 shares of the stock were exchanged, compared to its average volume of 681,709. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The firm has a fifty day moving average of $120.39 and a 200 day moving average of $116.25. The company has a market cap of $7.78 billion, a PE ratio of -19.06, a price-to-earnings-growth ratio of 8.13 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm's revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the sale, the director owned 429,973 shares in the company, valued at $55,303,127.26. This trade represents a 1.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.